Genetic Basis of the Metabolic Syndrome

Document Type : Review Article

Authors

1 Department of Genetics, School of Basic Sciences, Shahrekord University, Shahrekord, Iran

2 Assistant Professor, Applied Physiology Research Center AND Child Growth and Development Research Center AND Research Institute for Primordial Prevention of Non-communicable Disease AND Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Genetics, School of Basic Sciences AND Research Institute of Biotechnology, Shahrekord University, Shahrekord, Iran

4 Professor, Child Growth and Development Research Center AND Research Institute for Primordial Prevention of Non-communicable Disease AND Department of Pediatrics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Metabolic syndrome (MetS) is a prevalent disorder in children and it is described as a group of risk factors including obesity, increased fasting blood sugar, increased triglyceride, high blood pressure and decreased high-density lipoprotein (HDL) levels. This multifactorial disorder has been considered as one of the leading causes of mortality throughout the world and has been considered as a major risk factor for type 2 diabetes mellitus and atherosclerotic cardiovascular diseases. Recent studies have shown that the syndrome is highly prevalent among overweight children and adolescents. The etiology of the metabolic syndrome is complex, and is determined by the interaction between genetic and environmental factors and their influence on the development of obesity, insulin resistance and various inflammatory processes. Recent findings on Iranian children and adolescents show the prevalent of 23%. In this review, we looked at the definition, prevalence etiology and the main determinant genes in the development of this disorder.

Keywords

References

  1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
  2. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28(7): 1769-78.
  3. Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med 2006; 3(9): 482-9.
  4. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23(5): 469-80.
  5. Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, Spiro A, III, et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157(8): 701-11.
  6. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition 1997; 13(1): 65.
  7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52(5): 1210-4.
  8. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149(7): 1514-20.
  9. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007; 8(5): 299-306.
  10. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97(10): 996-1001.
  11. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21(6): 961-7.
  12. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353(9164): 1547-57.
  13. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47(10): 1643-9.
  14. Roche HM, Phillips C, Gibney MJ. The metabolic syndrome: the crossroads of diet and genetics. Proc Nutr Soc 2005; 64(3): 371-7.
  15. Barroso I, Luan J, Middelberg RP, Harding AH, Franks PW, Jakes RW, et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 2003; 1(1): E20.
  16. Le Marchand-Brustel Y, Gual P, Gremeaux T, Gonzalez T, Barres R, Tanti JF. Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling. Biochem Soc Trans 2003; 31(Pt 6): 1152-6.
  17. Sutton BS, Weinert S, Langefeld CD, Williams AH, Campbell JK, Saad MF, et al. Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Hum Genet 2005; 117(2-3): 107-18.
  18. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37(2): 268-85.
  19. Kondo H, Shimomura I, Matsukawa Y, Kumada M, Takahashi M, Matsuda M, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002; 51(7): 2325-8.
  20. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 2004; 43(7): 1195-200.
  21. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18(1): 45-8.
  22. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10(9): 1921-30.
  23. Ridderstrale M, Carlsson E, Klannemark M, Cederberg A, Kosters C, Tornqvist H, et al. FOXC2 mRNA Expression and a 5' untranslated region polymorphism of the gene are associated with insulin resistance. Diabetes 2002; 51(12): 3554-60.
  24. Kotzka J, Muller-Wieland D. Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Ther Targets 2004; 8(2): 141-9.
  25. Bosy-Westphal A, Onur S, Geisler C, Wolf A, Korth O, Pfeuffer M, et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond) 2007; 31(5): 784-90.
  26. Bellia A, Giardina E, Lauro D, Tesauro M, Di FG, Cusumano G, et al. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr Metab Cardiovasc Dis 2009; 19(7): 455-61.
  27. Carmelli D, Cardon LR, Fabsitz R. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments? Am J Hum Genet 1994; 55(3): 566-73.
  28. Edwards KL, Newman B, Mayer E, Selby JV, Krauss RM, Austin MA. Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol 1997; 14(3): 241-53.
  29. Austin MA, Edwards KL, McNeely MJ, Chandler WL, Leonetti DL, Talmud PJ, et al. Heritability of multivariate factors of the metabolic syndrome in nondiabetic Japanese americans. Diabetes 2004; 53(4): 1166-9.
  30. Chen W, Srinivasan SR, Elkasabany A, Berenson GS. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study. Atherosclerosis 1999; 145(1): 197-205.
  31. Lee KE, Klein BE, Klein R. Familial aggregation of components of the multiple metabolic syndrome in the Framingham Heart and Offspring Cohorts: Genetic Analysis Workshop Problem 1. BMC Genet 2003; 4(Suppl 1): S94.
  32. Wu KD, Hsiao CF, Ho LT, Sheu WH, Pei D, Chuang LM, et al. Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study. Hypertens Res 2002; 25(4): 529-36.
  33. Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: a systematic review. Obes Rev 2011; 12(11): 952-67.
  34. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002; 51(10): 3120-7.
  35. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157(8): 821-7.
  36. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280(22): 21553-60.
  37. Yamada Y, Ichihara S, Kato K, Yoshida T, Yokoi K, Matsuo H, et al. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet 2008; 45(1): 22-8.
  38. Kisfali P, Mohas M, Maasz A, Hadarits F, Marko L, Horvatovich K, et al. Apolipoprotein A5 IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ J 2008; 72(1): 40-3.
  39. Kisfali P, Mohas M, Maasz A, Polgar N, Hadarits F, Marko L, et al. Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2010; 20(7): 505-11.
  40. Maasz A, Kisfali P, Horvatovich K, Mohas M, Marko L, Csongei V, et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res 2007; 13(3): 243-7.
  41. Hsu LA, Ko YL, Chang CJ, Teng MS, Wu S, Hu CF. Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. Clin Chem Lab Med 2008; 46(12): 1714-9.
  42. Fatemi SG, Emadi-Baygi M, Nikpour P, Kelishadi R, Hashemipour M. Absence of Association between -1131T>C Polymorphism in the Apolipoprotein APOA5 Gene and Pediatric Metabolic Syndrome. Iran J Pediatr 2014; 24(3): 319-22.
  43. Guettier JM, Georgopoulos A, Tsai MY, Radha V, Shanthirani S, Deepa R, et al. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 2005; 90(3): 1705-11.
  44. Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999; 99(14): 1872-7.
  45. Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007; 38(4): 444-51.
  46. Niculescu LS, Vladica M, Sima AV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun 2010; 391(1): 587-91.
  47. Pollex RL, Hanley AJ, Zinman B, Harris SB, Khan HM, Hegele RA. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis 2006; 184(1): 121-9.
  48. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17(11): 2753-8.
  49. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992; 33(4): 447-54.
  50. Ranjith N, Pegoraro RJ, Rom L. Lipid profiles and associated gene polymorphisms in young Asian Indian patients with acute myocardial infarction and the metabolic syndrome. Metab Syndr Relat Disord 2009; 7(6): 571-8.
  51. Sima A, Iordan A, Stancu C. Apolipoprotein E polymorphism--a risk factor for metabolic syndrome. Clin Chem Lab Med 2007; 45(9): 1149-53.
  52. Olivieri O, Martinelli N, Bassi A, Trabetti E, Girelli D, Pizzolo F, et al. ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome. Clin Exp Med 2007; 7(4): 164-72.
  53. Onat A, Komurcu-Bayrak E, Can G, Kucukdurmaz Z, Hergenc G, Erginel-Unaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels. Nutrition 2010; 26(10): 975-80.
  54. Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T, et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 2007; 191(2): 298-304.
  55. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 2003; 114(1): 87-98.
  56. Thompson A, Di AE, Sarwar N, Erqou S, Saleheen D, Dullaart RP, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299(23): 2777-88.
  57. Junyent M, Lee YC, Smith CE, Arnett DK, Tsai MY, Kabagambe EK, et al. The effect of a novel intergenic polymorphism (rs11774572) on HDL-cholesterol concentrations depends on TaqIB polymorphism in the cholesterol ester transfer protein gene. Nutr Metab Cardiovasc Dis 2010; 20(1): 34-40.
  58. Ozsait B, Komurcu BE, Poda M, Can G, Hergenc G, Onat A, et al. CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu Kardiyol Derg 2008; 8(5): 324-30.
  59. Sandhofer A, Tatarczyk T, Laimer M, Ritsch A, Kaser S, Paulweber B, et al. The Taq1B-variant in the cholesteryl ester-transfer protein gene and the risk of metabolic syndrome. Obesity (Silver Spring) 2008; 16(4): 919-22.
  60. Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 2001; 27(1): 1-9.
  61. Horikoshi M, Hara K, Ito C, Nagai R, Froguel P, Kadowaki T. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 2007; 50(4): 747-51.
  62. van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, Strengman E, van Haeften TW, Hofker MH, et al. Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 2007; 50(1): 59-62.
  63. Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev 2008; 9(3): 246-50.
  64. Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A, et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 2008; 57(5): 1419-26.
  65. Attaoua R, Ait El MS, Lautier C, Kaouache S, Renard E, Brun JF, et al. Association of the FTO gene with obesity and the metabolic syndrome is independent of the IRS-2 gene in the female population of Southern France. Diabetes Metab 2009; 35(6): 476-83.
  66. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes 2005; 54(10): 3043-8.
  67. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol Genet Metab 2005; 86(1-2): 293-9.
  68. Andersen G, Overgaard J, Albrechtsen A, Glumer C, Borch-Johnsen K, Jorgensen T, et al. Studies of the association of the GNB3 825C>T polymorphism with components of the metabolic syndrome in white Danes. Diabetologia 2006; 49(1): 75-82.
  69. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 2008; 19(2): 65-73.
  70. Ferre P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 2007; 68(2): 72-82.
  71. Liu JX, Liu J, Guo Q, Liu J. [Association of sterol regulatory element binding protein-1c genetic polymorphisms rs2297508 and rs11868035 with type 2 diabetes mellitus in Gansu Han and Dongxiang population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012; 29(3): 328-33.
  72. Felder TK, Oberkofler H, Weitgasser R, Mackevics V, Krempler F, Paulweber B, et al. The SREBF-1 locus is associated with type 2 diabetes and plasma adiponectin levels in a middle-aged Austrian population. Int J Obes (Lond) 2007; 31(7): 1099-103.
  73. Liu JX, Liu J, Li PQ, Xie XD, Guo Q, Tian LM, et al. Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes mellitus, insulin resistance and blood lipid levels in Chinese population. Diabetes Res Clin Pract 2008; 82(1): 42-7.
  74. Nikpour P, Miranzadeh-Mahabadi H, Emadi-Baygi M, Kelishadi R. Association of rs8066560 variant in the sterol regulatory element-binding protein 1 (SREBP-1) and miR-33b genes with hyperglycemia and insulin resistance. J Pediatr Endocrinol Metab 2014; 27(7-8): 611-5.
  75. Miranzadeh-Mahabadi H, Nikpour P, Emadi-Baygi M, Kelishadi R. Comparison of TaqMan real-time and tetra-primer ARMS-PCR techniques for genotyping of rs8066560 variant in children and adolescents with metabolic syndrome. Adv Clin Exp Med 2015.
  76. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107(3): 363-9.
  77. Hsu LA, Chang CJ, Wu S, Teng MS, Chou HH, Chang HH, et al. Association between functional variants of the ICAM1 and CRP genes and metabolic syndrome in Taiwanese subjects. Metabolism 2010; 59(12): 1710-6.
  78. Komurcu-Bayrak E, Erginel-Unaltuna N, Onat A, Ozsait B, Eklund C, Hurme M, et al. Association of C-reactive protein (CRP) gene allelic variants with serum CRP levels and hypertension in Turkish adults. Atherosclerosis 2009; 206(2): 474-9.
  79. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3): 347-55.
  80. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156(11): 1070-7.
  81. Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006. Arch Pediatr Adolesc Med 2009; 163(4): 371-7.
  82. Moraes AC, Fulaz CS, Netto-Oliveira ER, Reichert FF. [Prevalence of metabolic syndrome in adolescents: a systematic review]. Cad Saude Publica 2009; 25(6): 1195-202.
  83. Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009; 7(6): 497-514.
  84. Lafortuna CL, Adorni F, Agosti F, De Col A, Sievert K, Siegfried W. Prevalence of the metabolic syndrome among extremely obese adolescents in Italy and Germany. Diabetes Research and Clinical Practice 2015; 88(1): 14-21.
  85. Chen W, Srinivasan SR, Elkasabany A, Berenson GS. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol 1999; 150(7): 667-74.
  86. Afkhami-Ardekani M, Zahedi-Asl S, Rashidi M, Atifah M, Hosseinpanah F, Azizi F. Incidence and trend of a metabolic syndrome phenotype among Tehranian adolescents: findings from the Tehran Lipid and Glucose Study, 1998-2001 to 2003-2006. Diabetes Care 2010; 33(9): 2110-2.
  87. Kelishadi R, Derakhshan R, Sabet B, Sarraf-Zadegan N, Kahbazi M, Sadri GH, et al. The metabolic syndrome in hypertensive and normotensive subjects: the Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2005; 34(3): 243-9.
  88. Schwandt P, Kelishadi R, Ribeiro RQ, Haas GM, Poursafa P. A three-country study on the components of the metabolic syndrome in youths: the BIG Study. Int J Pediatr Obes 2010; 5(4): 334-41.
  89. Schwandt P, Kelishadi R, Haas GM. Ethnic disparities of the metabolic syndrome in population-based samples of german and Iranian adolescents. Metab Syndr Relat Disord 2010; 8(2): 189-92.
  90. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366(9491): 1059-62.
Journal of Isfahan Medical School
Volume 33, Issue 327 - Serial Number 327
January and February 2015
Pages 355-367

Files

History

  • Receive Date: 04 August 2014
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics